

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.-72. (Canceled)

<sup>1</sup>  
73. (Previously Presented) An isolated polypeptide comprising SEQ ID NO:392.

<sup>2</sup>  
74. (Previously Presented) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue, and wherein said polypeptide is not SEQ ID NO:393.

<sup>3</sup>  
75. (Previously Presented) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

<sup>4</sup>  
76. (Previously Presented) An isolated polypeptide comprising amino acid residues 1-27 of SEQ ID NO:392, or a sequence having at least 90% identity to said polypeptide, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

<sup>5</sup>  
77. (Previously Presented) An isolated polypeptide comprising an amino acid sequence having at least 90% identity to amino acid residues 1-27 of SEQ ID NO:392, wherein said polypeptide is over expressed in ovarian cancer relative to normal ovarian tissue.

<sup>6</sup>  
78. (Previously Presented) A fusion polypeptide comprising a polypeptide according to any one of claims <sup>1-5</sup>73-77.

<sup>7</sup>  
79. (Previously Presented) A composition comprising a polypeptide according to any one of claims <sup>1-5</sup>73-77 and at least one physiologically acceptable excipient.

~~80.~~<sup>80</sup> (Previously Presented) A composition comprising a polypeptide according to any one of claims ~~73-77~~<sup>1-5</sup> and at least one adjuvant.

~~81.~~<sup>81</sup> (Previously Presented) The composition of claim ~~80~~<sup>8</sup>, wherein the adjuvant is selected from the group consisting of: an MPL, QS21 and AS-2.